|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0210 - 0.0235|
|52 Week Range||0.0200 - 0.0900|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Research recently published in the Journal of Molecular Neuroscience showed that KLS-13019 was 200 times more potent, 10 times more bioavailable, 5 times safer and 1000 times more effective than CBD.
Medical Marijuana, Inc. ("the Company") (OTC: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® received a Bronze Best in Biz Award for Most Innovative Product of the Year – Consumer for its high-quality hemp-derived cannabidiol (CBD) products. Also, Kannaway® CEO Blake Schroeder received a Bronze Award for Executive of the Year – Small Companies.
While cannabis has gone from a criminalized drug to a multibillion-dollar boom in recent years, very little data exists on how interest and consumer demand differ around the country, according to Michael Coleman, the vice president of sales and marketing at Medical Marijuana Inc (OTC: MJNA), told Benzinga. "We believe this study can be useful for cannabis executives and entrepreneurs who are looking to make strategic decisions about which markets to enter," he said of the company's most recent report on geographical interest on cannabis across the U.S. The following are highlights from Medical Marijuana Inc.'s report on interest in marijuana in cities nationwide.
Medical Marijuana (OTC: MJNA) announced that its major investment company AXIM Biotechnologies (OTCQB: AXIM) is making its cannabinoid-based chewing gum to treat chemotherapy-related symptoms. The chewing gum with dronabinol, a synthetic form of tetrahydrocannabinol (THC), is being manufactured through AXIM's contract manufacturer Eurofins Amatsigroup in Belgium. It will be used in AXIM's upcoming clinical studies on cannabis as a treatment […]The post AXIM to Launch CBD Chewing Gum to Treat Chemotherapy Symptoms appeared first on Market Exclusive.
A series of earnings reports from big companies including Slang Worldwide Inc (OTC: SLGWF) and TILT Holdings Inc (OTC: SVVTF) provided evidence that “the slow rollout of Massachusetts' recreational licenses has finally hit the earnings of cannabis companies who were slow to recognize the effects,” Green Market Report CEO Debra Borchardt told Benzinga. In other news, we found out that a weed-themed show is hitting the runway at the New York Fashion Week, the product of a collaboration between bold fashion designer Korto Momolu —featured on the show "Project Runway" —and Women Grow, the largest networking organization for women in the cannabis and hemp industries. "To sum it up in one phrase: it's 'for women, by women,'" Momolu told Benzinga.
iAnthus Capital Holdings (CSE: IAN) (OTCQX: ITHUF) reported its financial results for the fiscal second quarter ended June 30. Revenue for the quarter was $19.20 million, up from $256,000 for the same period of last year. The company posted a loss of $9.29 million, or $0.06 loss per share, versus a loss of $35.44 million, or […]The post Cannabis Stock News Daily Roundup August 27 appeared first on Market Exclusive.
If you’ve been paying attention to the sunscreen scene of late, you’ve probably seen how tropical destinations like Hawaii and Key West are banning common sunscreen chemicals oxybenzone and octinoxate since they damage delicate marine ecosystems. According to Punjabi, the benefits center around the anti-inflammatory properties of CBD, which can help “almost every skin condition you can think of—from eczema to acne.” Since the skin doesn’t absorb CBD as well as inhaling or ingesting it—which allows it to enter the bloodstream—CBD-based skincare products are a great “gateway” product for consumers new to the hemp industry.
A recent study revealed research findings around chemotherapy-induced peripheral neuropathy, or CIPN, and the potential for CBD as a treatment. The study, conducted by Kannalife, a company in the Medical Marijuana Inc (OTC: MJNA) portfolio, and published in the Journal of Molecular Neuroscience, showed that both CBD and the company's proprietary CBD-like molecule, KLS-13019, had protective action on the mitochondrial exchanger known to increase calcium levels — and therefore neuropathic pain — in patients taking the chemotherapy drug paclitaxel. It's actually a greater difference in potency," said Dr. Doug Brenneman, Kannalife's lead scientist.
GrowGeneration (OTCQX: GRWG) has purchased the assets of GreenLife Garden Supply, including two locations in Maine and one in New Hampshire. The acquisition brings the company's total retail and warehouse locations to five that services the growing number of commercial cultivators in the New England market. Target Group (OTCQB: CBDY) subsidiary Canary Rx has submitted a site […]The post Cannabis Stock News Daily Roundup May 15 appeared first on Market Exclusive.
It’s been an exciting 12-months for cannabis research. Every year, researchers discover more about marijuana and its effects. Brief Overview: After comparing the hospital records of more than a million heart-attack patients, researchers from the University of Colorado discovered that those who had used cannabis in the past were significantly less likely to die during hospitalization.
Medical Marijuana (OTC: MJNA) subsidiary Phyto Animal Health announced the launch of its newest cannabidiol pet product, Skin Vitality. The salve is intended to treat itching, support muscle and skin recovery and provide relief for hot spots, wounds, bug bites, flea dermatitis and rashes. GB Sciences (OTCQB: GBLX), a partner in GB Sciences Louisiana, said that all cultivation […]The post Cannabis Stock News Daily Roundup April 17 appeared first on Market Exclusive.
Marijuana stocks have been all the rage as legalization for medical and personal use has expanded. Leading the way is superstar Canopy Growth (NYSE:CGC). CGC has been riding high as it continues to see rising sales and has racked up some major deals with blue-chip companies such as Constellation Brands (NYSE:STZ).Source: Shutterstock There's a reason why Canopy could be one of the marijuana stocks first real winners on the race to profitability. Part of the reason is that Canopy is forward thinking.Just as it made some of the first moves into cannabis-infused drinks and other products with its STZ partnership, it's doing so with its latest deals. That will have it front and center in the animal and pet health marketplace. Don't laugh. Petcare is a booming and thriving business. Fertile ground for marijuana stocks to profit.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnd now, Canopy Growth has the chance to be the leading cannabis stock in the sector. A Big Market for the Marijuana StocksIt's no secret that Americans love their pets. A 2012 Harris Interactive survey found that 9 out 10 respondents viewed their companion pets as a member of the family. The survey also found that these respondents were willing to do whatever is necessary to ensure the health of their pet. And in that love and willingness, many Americans tend to spend almost nearly as much money on them as we do our own children.The American Pet Product Association data shows that annual expenditures by consumers for their pets have grown in each of the last 18 years. This includes during the Great Recession. Last year alone, Americans spent a whopping $72.56 billion on their pets. This includes $18.3 billion on veterinary care and $15.5 billion on supplies and over-the-counter medicines. This year, the APPA estimates that number will surge to more than $75 billion. The truth is, American's are very willing to spend on their fur babies.What does this have to do with marijuana stocks?While cats and dogs are very different than people, they do benefit from some of the same treatments for ailments. A lot of feline and canine drugs have been derived from their human counterparts. For example, our vet prescribes half a Benadryl tablet for our dog when his spring allergies start.With that, it stands to reason that dogs and cats may benefit from similar positive health-effects from cannabinoid and hemp-based CBD products. Already, several studies are underway with the both Colorado State University and the University of Pennsylvania School of Veterinary Medicine looking into CBD treatments for pets with osteoarthritis/joint pain and epilepsy. Meanwhile, just as there is a big and growing market for human supplements using CBD, there's massive potential for pet products as well.For the various marijuana stocks, this is a huge untapped market that they certainly can compete in, now that the Farm Bill has passed and hemp-based CBD is legal in many items. For Canopy Growth, the potential seems very big considering its recent moves. Canopy Growth Could Be the Leading Marijuana Stock for PetsCGC is poised to win in the booming pet care market thanks to another smart partnership. Around the end of March, Canopy cut a deal with Sequential Brands Group. The deal with Sequential puts CGC right into the thick of the pet care market as the collaboration focuses on the pair developing new hemp-derived cannabidiol (CBD) products for animals. The deal was sort of swept under the rug as other marijuana stock news was breaking around that time. But in the deal, was a huge coup for Canopy. And that was Martha Stewart.Yes, that Martha Stewart.The homemaker and entertaining queen provides plenty of brand cache for Canopy as she will become a strategic advisor on the firm's pet and hemp-product lines. Stewart has long been a pet advocative and her chow chows have become stars in their own right. With her on board, sales for whatever CGC develops could quickly find a foothold and command some high market share in the CBD pet product sector.One of the chief reasons why Canopy has been crushing other marijuana stocks has been the strength of its celebrity and major corporate partnerships. The firm has been able to get out in front of some major trends -- like CBD-infused drinks -- and has been able to capitalize on that with big deals. Pets and animal health will be no different. By adding Martha to the mix, it legitimizes its future products and gives it a major edge on supermarket shelves. That's something other pet-focused marijuana stocks like Medical Marijuana, Inc. (NASDAQ:MJNA) or CannTrust Holdings (NYSE:CTST) may not be able to match.All in all, it's just another reason why CGC is pulling away from the pack. Forget the Other Marijuana StocksThe reality is, the pot sector is quickly turning into a one or two horse race with Canopy leading the way. The firm continues to make major transformative deals to get itself out in front of major trends. It's under the rug deal with Sequential Brans puts it right front and center in a huge and growing market. The branding with Martha Stewart will only enhance that further. For investors, it's just another example of why CGC is the cannabis stock to own.As of this writing, Aaron Levitt did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Best Dividend Stocks to Buy for Every Investor * 7 Catalysts That Will Send Marijuana Stocks Soaring in 2019 * 8 Risky Stocks to Watch as Earnings Season Kicks Off Compare Brokers The post Pot for Pets? Canopy Growth Is on the Bleeding-Edge of Marijuana Stocks appeared first on InvestorPlace.
Medical Marijuana (OTC: MJNA) reported that its portfolio company AXIM Biotechnologies (OTCQB: AXIM) has been granted a patent by the United States Patent and Trademark Office (USPTO) for a method to treat atopic dermatitis using cannabinoids. The USPTO has issued a notice of allowance for the patent to the company for a method to treat […]The post AXIM Biotechnologies Gets U.S. Patent for CBD Cream to Treat Atopic Dermatitis appeared first on Market Exclusive.
California-based Medical Marijuana (OTC: MJNA), which makes and sells hemp-based products through subsidiaries, said that its HempMeds subsidiary expanded its retailing network by securing partnerships with more retailers. HempMeds, a retailer and distributor of hemp CBD oil products, formed partnerships with nearly 39 retailers – including major retailer Shopaholic Boutique – to sell its hemp […]The post Medical Marijuana Adds More Locations to Retail Network appeared first on Market Exclusive.
Medical Marijuana, Inc. (OTCMKTS:MJNA) has announced that subsidiary Kannaway® has placed a substantial purchase order from AXIM Biotechnologies (OTCMKTS:AXIM) for its CBD nutraceutical chewing gum. Kannaway® creating a nutraceutical brand Kannaway is a lifestyle network offering CBD hemp products. Blake Schroeder, the Chief Executive Officer, said that the subsidiary was proud to work together with […]The post Medical Marijuana, Inc. Affiliate Kannaway In CBD Gum Partnership With AXIM appeared first on Market Exclusive.
Cannabidiol, or CBD, products are now included in the Prescribers' Digital Reference -- formerly known as the Physicians' Desk Reference -- for the first time ever. The companies are HempMeds and Kannaway, two subsidiaries of Medical Marijuana Inc (OTC: MJNA). Medical Marijuana Inc CEO Stuart Titus told Benzinga the company became the first CBD company to be listed in the Prescribers’ Digital Reference, a book and online database containing drug manufacturers' prescribing information, used by doctors, pharmacists and other health care practitioners across the United States.
The FDA is holding a hearing today to look into the science and safety of products containing cannabis and CDB. Stuart Titus, Medical Marijuana Inc CEO, is attending the hearing, and joins Yahoo Finance with his take.